Zimbabwe

Praziquantel Donation Program

Merck KGaA’s Praziquantel Donation Program, in partnership with the World Health Organization (WHO), aims to fight schistosomiasis in Africa. Schistosomiasis is a parasitic worm disease that is the second most prevalent and devastating parasitic disease in tropical countries after malaria. Infection occurs when human skin comes into contact with fresh water contaminated by snails carrying the schistosome parasites, which migrate through the body and spread the infectious disease. It represents the 2nd most severe burden for African children after malaria, and is considered as one of the most neglected tropical diseases. The consequences of an infection are particularly serious for children, as schistosomiasis stunts growth and cognitive development and also lead to anemia. WHO reports more than 200 million infected people in Americas, Africa, the Middle East, Southeast and the Western Pacific.

ViiV Healthcare Collaborative Research Program for Resource-Poor Settings

ViiV Healthcare is committed to the development of new molecules that target unmet medical needs in HIV. The treatment of children with HIV/AIDS remains a significant unmet medical need and there is a pressing need for new medicines to tackle problems such as drug resistance, complex treatment regimens, and side effects associated with current treatments.

ViiV Healthcare Access to ARVs

In the Least Developed Countries and sub-Saharan Africa GlaxoSmithKline has offered its HIV/AIDS medicines at not-for-profit (nfp) prices since 2001. ViiV Healthcare will maintain this commitment, and will include the additional products in its portfolio. All of ViiV Healthcare's ARVs are now available at not-for-profit prices to public sector customers and not-for-profit organizations in all Least Developed Countries and all of sub-Saharan Africa - 64 countries in total.

Regional Psychosocial Support Initiative

In Southern and East Africa, the Novartis Foundation aims to improve livelihoods and future prospects of children and adolescents affected by HIV/AIDS.

PMTCT: Abbott Rapid HIV Test Donation Program

Each year, approximately 800,000 babies around the world become infected with HIV during their mothers´ pregnancy, during birth or through breastfeeding.

Pfizer Diflucan Partnership

Pfizer created the Diflucan Partnership in 2000 to provide treatment for two AIDS-related fungal infections in developing countries. Since the program's inception, Pfizer has over provided USD 1.1 billion of products and its program partners distribute millions of Diflucan (fluconazole) treatments free of charge to governments and NGOs in 63 developing countries in Africa, Asia, the Caribbean and Latin America. Pfizer has also provided training and education materials to 20,000 healthcare professionals.

Novartis Coartem

Coartem is the first World Health Organization-prequalified fixed-dose, artemisinin-based combination therapy (ACT) antimalarial, approved by stringent regulatory authorities and on the WHO Model List of Essential Medicines. Coartem is fast-acting and cures over 97% of patients after a 3-day treatment course. Coartem combines artemether, a derivative of artemisinin (from the Chinese medicinal plant Artemisia annua), with a synthetic substance, lumefantrine, which has not been used as a monotherapy.

Merck & Co., Inc. HIV/AIDS Programs - Africa

In 2009, with support from The Merck Company Foundation, the Earth Institute at Columbia University launched a community health worker training program to strengthen community health services for over 400,000 people in 10 African countries as part of the Millennium Villages project. The initiative aims to develop a professional cadre of 800 community health workers to fill a critical gap in primary healthcare provision for rural communities throughout Africa.

Leprosy Elimination

Novartis is providing free treatment for leprosy patients worldwide through its multi-drug therapy.

Humana: Total Control of the Epidemic

'Only people can liberate themselves from the AIDS epidemic'. These are the motivating words behind the Total Control of the Epidemic (TCE) program, which was created by the International Humana People to People Movement. Driven by a grassroots door-to-door approach, TCE has been completed in 24 areas with 2,340,000 inhabitants and at present is operating in 62 areas with 6,170,000 inhabitants in Africa, 2 areas with 200,000 inhabitants in India and 3 areas with 300,000 inhabitants in China.

Pages